Vir Biotechnology has concluded subject enrolment for the Phase III Eclipse 1 trial assessing the efficacy and safety of tobevibart and elebsiran combination for chronic hepatitis delta (CHD). This trial is part of the company’s Eclipse registrational programme, which also includes the ongoing Eclipse 2 and Eclipse 3 studies. Eclipse 1 aims to provide safety and efficacy data required for submissions to regulatory agencies globally, and in the US and Europe. The last Eclipse 1 participant is expected to reach the primary endpoint in the fourth quarter of 2026. Topline data are anticipated in the first quarter of 2027. Vir Biotechnology CEO Marianne De Backer said: “Reaching full enrolment in our Eclipse 1 Phase III clinical trial marks an essential milestone as we work towards submission of the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta to global regulatory agencies.

Full report : Vir Biotechnology concludes Eclipse 1 Phase III trial enrolment for chronic hepatitis delta.